Mills Kenneth T. - 16 Jul 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
16 Jul 2024
Net transactions value
-$24,130
Form type
4
Filing time
18 Jul 2024, 17:05:11 UTC
Previous filing
16 May 2024
Next filing
26 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $752 +200 +0.05% $3.76 408,235 16 Jul 2024 Direct F1
transaction RGNX Common Stock Sale $2,752 -200 -0.05% $13.76 408,035 16 Jul 2024 Direct F1
transaction RGNX Common Stock Options Exercise $8,310 +2,210 +0.54% $3.76 410,245 17 Jul 2024 Direct F1
transaction RGNX Common Stock Sale $30,440 -2,210 -0.54% $13.77 408,035 17 Jul 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -200 -0.25% $0.000000 81,154 16 Jul 2024 Common Stock 200 $3.76 Direct F1, F3
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -2,210 -2.7% $0.000000 78,944 17 Jul 2024 Common Stock 2,210 $3.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $13.76 to $13.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.